CapsoVision (CV) Net Equity Issued and Repurchased (2024 - 2025)
CapsoVision (CV) reported Net Equity Issued and Repurchased of -$202000.0 for Q3 2025, down 102.03% on a YoY basis from $9.9 million in Q3 2024, and down 104.04% sequentially from $5.0 million in Q4 2024.
CapsoVision (CV) Net Equity Issued and Repurchased (2024 - 2025) Analysis & Trends
CapsoVision (CV) has 2 years of Net Equity Issued and Repurchased data on file, last reported at -$202000.0 in Q3 2025.
- For the quarter ending Q3 2025, Net Equity Issued and Repurchased fell 102.03% year-over-year to -$202000.0; the trailing twelve-month figure through Dec 2025 stood at $14.7 million (changed N/A YoY), and the FY2024 full-year result was $15.0 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased slipped to -$202000.0 in Q3 2025, from $5.0 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $9.9 million in Q3 2024 to a low of -$202000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 97.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 12.70 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | CapsoVision | 162.07 Mn | 151.95 Mn | 1.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -202,000.00 |
| Sep 30, 2025 | -202,000.00 |
| Dec 31, 2024 | 5.00 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Sep 30, 2024 | 9.93 Mn |
| Sep 30, 2024 | 9.93 Mn |